Physician profile
George E Sloan
NPI 1124097993
$12,003.26
in general payments reported to CMS, 2019-2025
55 companies · $1,218 in 2025
The $1,218 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,061 · 2020: $582 · 2021: $346 · 2022: $265 · 2023: $647 · 2024: $884 · 2025: $1,218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,568 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,567.76 |
| Education | $181.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $4,226.98 | 2019 | |
| Tosoh Bioscience, INC. | $948.00 | 2019 | |
| Novartis Pharmaceuticals Corporation | $765.54 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $566.03 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $484.24 | 2019-2025 | Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $366.82 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $363.43 | 2019-2020 | |
| Pfizer INC. | $291.42 | 2019-2025 | |
| Genentech USA, INC. | $261.41 | 2019-2025 | Venclexta |
| Celgene Corporation | $256.66 | 2019-2025 | Pomalyst, Reblozyl |
| Astellas Pharma US INC | $250.71 | 2019-2023 | |
| Glaxosmithkline, LLC. | $241.90 | 2022-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $205.94 | 2021-2025 | Trodelvy |
| Stryker Corporation | $196.89 | 2021 | |
| Janssen Biotech, INC. | $191.03 | 2019-2020 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Sloan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.